There were 26 press releases posted in the last 24 hours and 154,419 in the last 365 days.

Mr. Jason Lok Joins Sirnaomics Senior Management Team as Chief Financial Officer

Advancing RNAi Therapeutics

Sirnaomics Inc.

GAITHERSBURG, MD, UNITED STATES, September 5, 2018 / -- Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that Mr. Jason Chun Sing Lok, has joined Sirnaomics senior management team as Chief Financial Officer. Mr. Lok is going to be responsible for planning, implementing, managing and controlling the financial-related activities of the company, including accounting, finance, forecasting, strategic planning, legal, deal analysis and structuring, investor relationship, partnership compliance, and private and institutional financing.

Prior to joining Sirnaomics, Mr. Lok was an executive director with China Resources Group and primarily focused on overseas healthcare investment opportunities. Before that he was a director with Credit Suisse's China Healthcare Investment Banking and Capital Markets team in Hong Kong, responsible for healthcare client coverage across Greater China region for Credit Suisse and led many high-profile IPOs, M&A and other strategic transactions for biotechnology and other healthcare clients. Throughout his 14 years of financing career, Mr. Lok has accumulated extensive experience and expertise in corporate finance and capital market transactions for the pharmaceutical and biotechnology industries. Mr. Lok started his career at PricewaterhouseCoopers and is a certified public accountant.

"We are very pleased to have Jason on board our senior management team, to lead our financial management function and to insure Sirnaomics will be in a sound and solid financial position. His strong experience and knowledge in finance and the capital market will greatly benefit both the Company's US and China operations, allowing the Company to be well positioned for potential partnership and the initial public offering," said Dr. Patrick Lu, President and CEO of the company.

"I am very excited to join Sirnaomics at this important time of its development, and look forward in bringing in my experience in finance and the capital market to help the Company to advance to the next level," Jason said. “Sirnaomics' innovative approach for treating fibrosis and oncology related diseases is extremely exciting and I am thrilled to be able to work along this impressive team to bring novel and transformational treatments to address highly unmet medical needs in the market," stated Mr. Jason Lok.

About Sirnaomics Clinical Programs

The leading compound of Sirnaomics STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA was demonstrated to inhibit the expression of their target mRNAs and combining the two siRNA’s produces a synergistic effect that diminishes pro-fibrogenic and pro-inflammatory factors. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with fibrosis including α-SMA, Col1A1, and Col3A1. Additional data suggests that reductions in TGF-β1 and COX-2 led to proapoptotic effects in fibroblasts. These observations suggest that STP705 has the potential for broad application in many inflammatory and fibrotic disease states. STP705 has already entered Phase 2a clinical study in USA and received clinical study approval from Chinese FDA for treatment of hypertrophic Scar. In addition, STP705 has received two orphan drug designations for treatments of Primary Sclerosing Cholangitis (PSC) and Cholangiocarcinoma (CCA) later last year. Recently, an IND application of STP705 for treatment of Cholangiocarcinoma received green light from US FDA, marking the first oncology program of the Company entering the clinical stage. Other clinical indications for the fibrotic diseases and cancers using STP705 or other RNAi therapeutic compounds are under development by Sirnaomics.

About Sirnaomics, Inc.

Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The company’s mission is to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the Company are: Innovation, Global Vision and Patient-Centered. Members of the senior management team have extensive experience in the biopharmaceutical, financial, clinical and business management arenas in both the USA and China. The company is supported with funding from private and institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual properties with an enriched product pipeline. The therapeutic areas of interest include fibrotic diseases and oncology.

George Ji, Senior VP
email us here